about
Medical management of high-grade astrocytoma: current and emerging therapies.Recent medical management of glioblastoma.Relationship between cognitive function and prognosis in glioblastoma.Conditional probability of long-term survival in glioblastoma: a population-based analysis.Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.Glioblastoma survival in the United States before and during the temozolomide era.Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.Socioeconomic status and glioblastoma risk: a population-based analysis.2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know.Dual-Energy CT Differentiates Contrast Staining From Hemorrhagic Conversion of Ischemic Stroke.Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging toolsThere is an exception to every rule-T2-FLAIR mismatch sign in gliomasNeuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendrogliomaIntroducing the Case-Based Reviews series: a new educational resource for brain tumor clinicians and traineesPlenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the youngPitfalls of a Mixed Metabolic Response at PET/CTNeuro-Oncology Practice Clinical Debate: stereotactic radiosurgery or fractionated stereotactic radiotherapy following surgical resection for brain metastasis
P50
Q34436053-51B97600-1373-475B-9C1D-0433594D25FDQ38013705-58BC713B-105E-4FA1-8919-6A1F4AB430D9Q38233450-5EDB42B0-1BE1-44F8-B782-576326608733Q39619773-0A03D499-B705-481C-A5D5-4656D17A8EA0Q39647870-3DD40CAA-50DF-44B1-9919-D5FA1BEB8C7EQ44016219-D3C53579-3AA9-4649-876B-65D969BEACB4Q44661518-7330ED41-370E-4D22-9A2D-269064B379D1Q46227922-0F59267D-FD59-42DB-B358-7D079454BF12Q48020675-A72D62B1-5356-4D76-AE70-779D06280813Q48045522-F9893AD3-39C2-4E8B-96E6-961BC2C77EB9Q48307043-84FE3CDA-3AE8-4584-9789-36384925C2EFQ58561754-72F119C9-F7CA-4A6E-B7C7-53DCB26F61A7Q90626978-372FD71A-17BC-4CF9-AEB1-1D18D7065BA2Q92446227-A0B12914-2392-43CC-AE26-AA1A8186A018Q92446703-D081278B-1D4A-4E19-B986-574AD9117DEAQ92513966-29CEF443-B162-45A2-AFC5-C8182A84C730Q92523393-8AEE8051-D50A-4C47-B272-0CF1F323C820Q96345910-632AFB83-4ABD-479D-B97E-B01D81A07E9E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Derek R Johnson
@ast
Derek R Johnson
@en
Derek R Johnson
@es
Derek R Johnson
@nl
Derek R Johnson
@sl
type
label
Derek R Johnson
@ast
Derek R Johnson
@en
Derek R Johnson
@es
Derek R Johnson
@nl
Derek R Johnson
@sl
prefLabel
Derek R Johnson
@ast
Derek R Johnson
@en
Derek R Johnson
@es
Derek R Johnson
@nl
Derek R Johnson
@sl
P106
P108
P21
P31
P496
0000-0002-4217-5517